

 Early Warning System

EIB-20230583

BAYER PHARMACEUTICAL RDI



## Quick Facts

Countries	Germany
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2024-11-26
Borrower	BAYER AG
Sectors	Industry and Trade
Investment Type(s)	Loan
Project Cost (USD)	\$ 2,649.14 million



---

## Project Description

According to the Bank's website, the project will support Bayer, an EU-based promoter, in its Research & Development (R&D) activities concerning its Pharmaceutical business.

In detail, R&D refers to its pharmaceutical product pipeline targeting unmet medical needs, in particular related to therapeutic areas of Cardiology, Oncology care, Ophthalmology, Women's Healthcare, Radiology as well as Cross-disease research platforms and other R&D project work.

The project supports an European promoter in its efforts to foster its competitive position in high value-added products by investing in R&D activities. It contributes to the targets of Horizon Europe priorities of strengthening the EU's scientific and technological foundations and European Research Area (ERA) and increasing innovation capacity, competitiveness, and the number of jobs in Europe. Moreover, the project corresponds to Article 309 point (c) Common interest, contributing to the PPG "Innovation, Digital and Human Capital RDI".

The products developed as a result of the project will address unmet medical needs, positively supporting the European effort in advancing the Sustainable Development Goal SDG3, "Ensure healthy lives and promote well-being for all at all ages". As such, the project would also improve the possibilities of social inclusion of people suffering from debilitating diseases including neglected diseases as addressed under this project, therefore the social value of the project is considered to be positive.



---

### Early Warning System Project Analysis

The R&D activities are expected to be carried out in existing facilities that are already used for the same purposes and that are not expected to change their scope due to the project. An Environmental Impact Assessment (EIA) is therefore not needed as per EIA Directive 2014/52/EU (amending Directive 2011/92/EU).

The full environmental details will however be investigated by the Bank's services during the project due diligence.



---

## Investment Description

- European Investment Bank (EIB)



---

## Private Actors Description

*Bayer Aktiengesellschaft* produces and markets healthcare and agricultural products. The Company manufactures products that include aspirin, antibiotics, anti-infectives, cardiovascular, oncology, central nervous system drugs, over-the-counter medications, diagnostics, and animal health products. Bayer Aktiengesellschaft serves customers in the States of Germany.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Bayer AG	Client	-



---

## Contact Information

*No contacts available at the time of disclosure.*

### ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

### ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: [complaints@eib.org](mailto:complaints@eib.org), by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: [http://www.eib.org/attachments/strategies/complaints\\_mechanism\\_policy\\_en.pdf](http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf)

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>





---

## Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - BAYER PHARMACEUTICAL RDI](#)